Mesoblast is described in the article as an Australian company that develops stem cell therapies. The piece characterizes Mesoblast as a stem‑cell therapy player that faced rough waters in 2020. It reports the company was given a financial lifeline when it raised $110 million. The article does not provide product-level detail, pipeline specifics, operating metrics, or stated future plans. The report also does not disclose the financing instrument or the terms of the transaction. Coverage frames the cash infusion as a lifeline for the company.

Total raised

$110M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2021